CHMP Recommends EU Approval of Roche’s Tecentriq in Combination with Abraxane as an Initial treatment for People with PD-L1-positive, Metastatic Triple-negative Breast Cancer
Recommendation based on the results of IMpassion130 study in triple-negative breast cancer, an aggressive type of breast cancer with high unmet medical need